


NEWSRELEASE

DELMEICA INVESTMENTS April 2007



Delmedica offers the private equity investor access to unique biotechnology opportunities that have the hallmarks of commercially successful ventures.



This April newsletter focuses on Fortune Apex Development ('Fortune Apex') as it continues to advance 'MUCOAD™' towards marketplace delivery. Negotiations with key stakeholders, licensees and industry representatives are ongoing alongside strategic Industry presentations. Fortune Apex is also generating interest with two new pipeline products.

in this issue

- A New Frontier
- March to Market
- Global Awareness
- New Product News
- Non-Executive Director

MUCOAD™ PRESENTS

'The New frontier for Drug Delivery'

Strategic BioSciences* have been approached to present MUCOAD™ technology at the Annual International Technology Forum in Washington DC May 13-15th.

The forum attracts key decision makers from the world's leading pharmaceutical companies seeking innovative technologies for commercialisation. Pharmaceutical Executives will attend a presentation by Fortune Apex Research Scientists and then further analyse the information in a structured Q&A Forum conducted by Strategic Biosciences.

An abstract of the presentation is available at the forum's website and will be circulated within the conference sales material.

www.technology-catalysts.com/annual_meeting/

* US Joint Venture partner with Fortune Apex

March to Market

Strategic BioSciences are making presentations to, and continuing negotiations with a number of key Pharmaceutical companies. Upon finalisation of these negotiations, media releases will be posted on the Fortune Apex website and circulated to Industry Press.

Fortune Apex continue to spread the word... presenting the Patented MUCOAD™ technology at a number of significant global conferences throughout the remainder of this year with the objective of securing evaluations, further licensing opportunities and ultimately, expediting market commercialisation.

Global Awareness

A Global MUCOAD™ PR Campaign will soon be circulated to key Pharmaceutical and Medical publications around the US.

The campaign has been prepared and will be circulated by Strategic BioSciences and is expected to generate significant exposure and interest within the US Pharmaceutical Community and elsewhere around the globe.

Campaign material is currently being reviewed by Company Lawyers and will be posted on the Fortune Apex website once approved.

New Product News

'Xylometazoline' and 'Metodopramide' have both been the subject of interest in Singapore recently.

A regional distribution and marketing company has targeted the two Fortune Apex compounds, expressing interest in their exclusive licensing and distribution rights in Singapore.

Meanwhile, Fortune Apex expects detailed information and product dossiers will be available for further evaluation and negotiation within 3-6 months.

Appointment of Non-Executive director

DMI are hoping to announce a significant new appointment...

Negotiations for the Non-Executive Director position continue and discussions have progressed with an individual whose appointment has been considered both important and influential.

It is expected that this appointment will influence the early commercialisation and ongoing success of DMI's Dunev Thermometer technology.

www.delmedicainvestments.com

DELMEICA

Delmedica Investments Ltd • 7 Temasek Boulevard • #06-01 • Suntec Tower 1 • Singapore 038987